Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.
Little is known about the risk of severe illness from respiratory syncytial virus infection in children with bronchopulmonary dysplasia. A prospective study was done of the natural history of…
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.
RSVIG infusions seemed safe and generally well tolerated and although some beneficial effect trends were seen for those with more severe disease who were treated there was no evidence that treatment with RSVIG resulted in reduced hospitalization and reduced ICU stays in all children with RSv disease.
Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database
This is the first prospective multicentre study from Germany that confirms the increased risk for severe RSV disease in preterms, in particular in those with CLD treated in the last 6 months before the onset of the infection.
Hospitalized Children With Respiratory Syncytial Virus Infection and Neuromuscular Impairment Face an Increased Risk of a Complicated Course
This is the first prospective multicenter study confirming the hypothesis that children with clinically relevant NMI face an increased risk for severe RSV-disease and seems reasonable to include NMI as a cofactor into the decision algorithm of passive immunization.
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
- J. Groothuis, S. King, D. Hogerman, P. Paradiso, E. Simões
- MedicineJournal of Infectious Diseases
- 1 February 1998
PFP-2 vaccine appears safe and immunogenic and may protect children with bronchopulmonary dysplasia against serious RSV disease on reinfection.
Increased child abuse in families with twins.
A regression analysis incorporating all of these variables showed that twin status was most predictive of subsequent abuse.